To be presented at 11th Annual Immunotherapy of Cancer (ITOC) Conference in Munich, Germany Marlborough, Massachusetts--(Newsfile Corp. - April 3,...
KANAZAWA, Japan, April 3, 2025 /PRNewswire/ -- Scientists at the Nano Life Science Institute (WPI-NanoLSI), Kanazawa University and colleagues have developed a...
Data published in Neuro-Oncology demonstrate promising safety profile and potential survival benefit when combining CAN-2409 and nivolumab with standard of...
– Remaining $60 Million of outstanding convertible notes to be repurchased post-close of pending UDENYCA divestiture – REDWOOD CITY, Calif.,...
Continues advancing clinical trial for INSTASYL siRNA lead product candidate PH-7623rd Cohort now fully enrolled in on-going clinical studyMarlborough, Massachusetts--(Newsfile...
Collaboration to apply Lunit's AI technologies across NCI's broad spectrum of cancer studies, aiming to accelerate personalized cancer care SEOUL,...
SHANGHAI, March 28, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading...
SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a biotechnology company...
UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinomaWALTHAM, Mass., March 28,...
PROVIDENCE, R.I., March 28, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company dedicated to advancing innovative...
- Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) -...
Châtillon, France, March 27, 2025 DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut...
Encouraging efficacy data in a murine mesothelioma model with a selective A2B adenosine receptor antagonist given as a single agent...
• Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with Hepatocellular Carcinoma...
Company to Host Conference Call Today, March 27, at 4:30pm ETBOCA RATON, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- INmune...
-Started Two New Clinical Trials, Collaborating with MD Anderson and The Netherlands Cancer Institute for Treatment of Ovarian and Colorectal Cancer-...
Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer...
A global collaboration agreement has been signed for the development and commercialization of a Granzyme B-targeted Positron Emission Tomography (PET)...
Pioneering cancer immunology company Asgard strengthens leadership team as it progresses its lead asset AT-108 towards clinical trials Shane brings...
AGOURA HILLS, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”),...